middle.news
Argenica Completes Phase 2 Dosing for ARG-007 Stroke Trial, Eyes FDA Fast Track
8:09am on Wednesday 30th of April, 2025 AEST
•
Biotechnology
Read Story
Argenica Completes Phase 2 Dosing for ARG-007 Stroke Trial, Eyes FDA Fast Track
8:09am on Wednesday 30th of April, 2025 AEST
Key Points
Phase 2 clinical trial dosing completed with 92 AIS patients
Data Safety Monitoring Board recommends trial continuation without protocol changes
Topline Phase 2 efficacy and safety data expected in Q3 2025
Preclinical studies show ARG-007 neuroprotection in traumatic brain injury models
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argenica Therapeutics (ASX:AGN)
OPEN ARTICLE